MEMBER SINCE 2012
Belén Garijo, MD
Chair, Executive Board and CEO, Merck KGaABelén Garijo is Chair of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany. She joined the company in 2011 as Chief Operating Officer of the Biopharma business, becoming President and CEO of Healthcare in 2015. In July 2020, Belén Garijo was appointed Vice Chairman of the Executive Board and Deputy CEO in addition to her role as CEO of the Healthcare business. She moved from Deputy CEO to CEO in May 2021.
Under her leadership, Healthcare at Merck KGaA, Darmstadt, Germany, has become a key player in the area of oncology, immunology and immuno-oncology, after the profound repositioning of the portfolio, the reorganization of R&D and the transformation of the commercial model. Belén Garijo has forged two major global alliances to further contribute to the portfolio’s maximization. She has also focused on globalization by expanding the business to growth markets as well as to Japan and the U.S.
Before joining Merck, Belén Garijo served as the Senior Vice President of Global Operations Europe at Sanofi-Aventis and Global Integration Leader of Genzyme after its acquisition by Sanofi. She previously held several local and global executive positions, both in R&D and commercial, at various companies at the forefront of the Healthcare sector.
She started her career as a practicing physician at La Paz hospital in Madrid before moving to the pharmaceutical industry. She is a medical doctor, specialized in clinical pharmacology.CEO Cancer Gold Standard™
Gold Standard Employer
Gold Standard Employer Since 2011Project Data Sphere, LLC
an independent initiative of the Life Sciences ConsortiumGrant Provider
Grant Provider Since 2017Merck KGaA
Merck KGaA, Darmstadt, Germany, the vibrant science and technology company, operates across healthcare, life science and performance materials. Around 53,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2017, Merck KGaA, Darmstadt, Germany, generated sales of € 15.3 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck, KGaA, Darmstadt, Germany, visit www.emdgroup.com.
FOUNDING MEMBER
Reshema Kemps-Polanco, MBA
Executive Vice President and U.S. Head, Novartis OncologyReshema Kemps-Polanco is Executive Vice President and US Head, Novartis Oncology, responsible for the commercialization of innovative cancer medicines, including complex platforms such as cell and gene therapy, and radiopharmaceuticals. With over 20 years of U.S. and global healthcare experience, she is pursuing a transformational growth strategy to sustain a leading position in the world’s largest healthcare market across oncology and hematologic diseases.
Reshema returned to Novartis in 2021 after spending seven years at Johnson and Johnson, where she served as President of Janssen’s Cardiovascular and Metabolism Unit in the U.S. and concurrently as President, Janssen Pharmaceuticals, Puerto Rico. Prior positions at Janssen include serving as Vice President across multiple roles in the U.S., as well as the Global Oncology organization. Before joining Johnson and Johnson, Reshema spent 15 years at Novartis where she led multiple commercial teams across oncology and specialty business units.
Reshema is a board member of the Healthcare Leadership Council, a coalition of chief executives focused on policies that make quality healthcare accessible to all Americans.
Reshema earned an M.B.A from Rutgers University, and M.A. in Industrial/Organizational Development from Louisiana Tech University and a B.A. from the University of Louisiana at Monroe.CEO Cancer Gold Standard™
Gold Standard Employer
Gold Standard Employer Since 2006 | Global Gold Standard Employer Since 2013"At Novartis Oncology, our mission is to discover new ways to improve and extend the lives of people with cancer. This starts with the health of our associates. Our accreditation with the CEO Cancer Gold Standard has provided us for the past 10 years with a valuable framework from which to structure our programs geared toward preventing cancer, providing support during the cancer journey, and encouraging the overall health and well-being of our associates."
Reshema Kemps-Polanco, MBAGold Standard Task Force Participation
Gold Standard Co-Chair, Accreditation Review Board Member & Member: Roy D. Baynes, MD, PhD, Senior Vice President & Head of Global Clinical Development, Chief Medical OfficerGlobal Gold Standard Task Force Participation
Global Gold Standard Subcommittee Member: Dawn Aubel, EdD, MS, MPH, APNc, Medical Science Liaison HematologyLife Sciences Consortium
LSC Task Force Participation
Task Force Member(s): Elizabeth Barrett, Chief Executive Officer, Novartis Oncology; Maya R. Said, Global Head, Oncology Policy and Market AccessNovartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit http://www.novartis.com.
MEMBER SINCE 2023
Heather Cianfrocco
PresidentHeather Cianfrocco is president of Optum. Cianfrocco joined UnitedHealth Group in 2008 where she held numerous leadership roles. She previously served as chief executive officer of Optum Rx and chief executive officer for Optum’s Health Services where she was responsible for behavioral health benefits, population health solutions and medical benefit management. Before that, she was chief executive officer of UnitedHealthcare Community & State, senior vice president of Health Advancement and Clinical Transformation for UnitedHealthcare Medicare & Retirement, and chief executive officer of state and regional health plans. In addition, she was a former member of the United Health Foundation Advisory Board.
Prior to UnitedHealth Group, Cianfrocco worked in private legal practices in Pittsburgh where she concentrated on corporate and securities law, representing health care entities in mergers and acquisitions. She earned a master’s degree in health care delivery science from Dartmouth College and a J.D. from Duquesne University School of Law.Optum
Optum is a leading information and technology-enabled health services business dedicated to helping make the health system work better for everyone. With more than 210,000 people worldwide, Optum delivers intelligent, integrated solutions that help to modernize the health system and improve overall population health. Optum is part of UnitedHealth Group.
MEMBER SINCE 2023
Maya R. Said, ScD
Founder and Chief Executive OfficerDr. Maya Said is the Founder and CEO of Outcomes4Me, a health technology company focused on providing patients diagnosed with cancer and other chronic diseases with personalized treatment options as well as outcomes information. Maya spent the last 20 years working in healthcare, primarily in the pharmaceutical industry with a focus on increasing innovation and access. Despite her extensive experience with healthcare systems globally, it wasn’t until she first became a patient herself that she realized much more can be done to improve outcomes and better serve the needs of patients. An engineer and scientist, she strongly believes that technology combined with early patient input can address many of the gaps patients experience today in navigating the healthcare system. Her conviction that technology-based solutions that empower patients can lead to better outcomes led her to create Outcomes4Me.
Prior to founding the company, she spent many years as a senior pharmaceutical executive at both Novartis and Sanofi leading global functions including: Market Access, Policy, R&D Strategy, and Business Development. Earlier in her career, Maya was a Partner at the Boston Consulting Group and a founding member of its Strategy Institute.
Maya trained at the Massachusetts Institute of Technology (MIT), earning dual degrees in Biology and Electrical Engineering and Computer Science (EECS) with a minor in Economics. She also holds a Master of Science in Toxicology, a Master of Engineering in Electrical Engineering, and Computer Science, and a Doctor of Science in Electrical Engineering, Computer Science, and Systems Biology, all from MIT. She has authored numerous scientific and strategy articles and was honored with the Carlton E. Tucker award for teaching excellence, the Department Head Recognition Award for major contribution to the EECS Department at MIT, and the Burchard Scholar for excellence in humanities and social sciences.Outcomes4Me
Outcomes4Me is an AI-driven patient empowerment platform that helps cancer patients take a proactive approach to their care, gaining access to personalized, evidence-based treatment options and information. The company is on a mission to democratize healthcare by providing real-time, evidence-based clinical information to cancer patients, ensuring they can effectively navigate through their disease and improve their outcomes. In doing so, Outcomes4Me is working to promote health equity by generating deeper insights that improve care, and accelerating research and access to innovation. Based in Boston, Massachusetts, Outcomes4Me is a woman-led company of seasoned healthcare, oncology, pharmaceutical, consumer, and technology veterans.
FOUNDING MEMBER
Albert Bourla, DVM, PhD
Chief Executive OfficerAlbert Bourla became Chief Executive Officer on January 1, 2019.
In his previous role, Albert was Pfizer’s Chief Operating Officer (COO), overseeing the company’s commercial strategy, manufacturing and global product development functions. Prior to being named COO, Albert was the Group President of Pfizer Innovative Health, responsible for the Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease, Vaccines and Consumer Healthcare business groups. He also created the Patient and Health Impact group, dedicated to developing solutions for increasing patient access, demonstrating the value of our innovations and ensuring broader business model innovation.
Albert has more than 25 years of experience with Pfizer and has held a number of senior global positions across a range of markets and disciplines, including Group President of Pfizer’s Global Vaccines, Oncology and Consumer Healthcare business and President and General Manager of Pfizer’s Established Products business.
Albert joined Pfizer’s Animal Health Division in 1993 as Technical Director of Greece. He held positions of increasing responsibility across Europe before moving to Pfizer Global Headquarters in New York in 2001 to assume the role of U.S. Group Marketing Director for Animal Health. In 2004, he became Vice President of Business Development and New Products Marketing; supervising Pfizer Animal Health global licensing and acquisition activities, as well as the unit’s R&D portfolio. In 2006, he was appointed Area President of Europe, Africa and Middle East, and in 2009, he assumed additional responsibilities for Asia and Pacific.
Albert is a Doctor of Veterinary Medicine and holds a Ph.D. in the Biotechnology of Reproduction from the Veterinary School of Aristotle University. Albert is a member of the Board of Directors of Pfizer Inc., the Pfizer Foundation and the Partnership for New York City.CEO Cancer Gold Standard™
Gold Standard Employer
Since 2008"At Pfizer we are committed to wellness through helping colleagues and patients find treatments and cures, and advancing the goal of preventing illness. The CEO Cancer Gold Standard is one way to help colleagues and their family members take responsibility for their health."
Albert Bourla, DVM, PhDGold Standard Task Force Participation
Task Force Member(s): Nicole Shaffer, DNP, CRNP-BC, COHN-S, FAAO, Director, Occupational Health & WellnessLife Sciences Consortium
LSC Task Force Participation
Task Force Member(s): Mace L. Rothenberg, MD, Chief Development Officer for Oncology, Global Product Development Group, PfizerProject Data Sphere, LLC
an independent initiative of the Life Sciences ConsortiumData Provider
Pioneering Data ProviderPfizer, Inc.
Good health is vital to all of us, and finding sustainable solutions to the most pressing health care challenges of our world cannot wait. That’s why we at Pfizer are committed to applying science and our global resources to improve health and well-being at every stage of life. We strive to provide access to safe, effective and affordable medicines and related health care services to the people who need them.
We have a leading portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas; and we have an industry-leading pipeline of promising new products that have the potential to challenge some of the most feared diseases of our time, like Alzheimer’s disease and cancer.
To ensure we can continue to deliver on our commitments to the patients, customers and shareholders who rely on us, we are focused on improving the way we do business; on operating with transparency in everything we do; and on listening to the views of all of the people involved in health care decisions. Through working in partnership with everyone from patients to health care providers and managed care organizations to world governments and non-governmental organizations, our goal is to ensure that people everywhere have access to innovative treatments and quality health care.
MEMBER SINCE 2009
Stephen H. Rusckowski
Chairman, President and Chief Executive OfficerSteve Rusckowski is Chairman, President and Chief Executive Officer of Quest Diagnostics. Since joining Quest Diagnostics as President and Chief Executive Officer in May 2012, Mr. Rusckowski has focused on transforming the company, based on its compelling vision of “Empowering better health with diagnostic insights.” Under his leadership, the company has refocused on its core diagnostic information services business, sold non-core assets, delivered disciplined deployment, including share repurchases and acquisitions, and simplified its organizational structure to better serve customers by removing complexity, speeding decision making and empowering employees. He was elected Chairman of the Board in December 2016.
Prior to joining Quest Diagnostics, Mr. Rusckowski was CEO of Philips Healthcare, which became the largest unit of Royal Philips Electronics under his leadership. He joined Philips in 2001 when it acquired the Healthcare Solutions Group he was leading at Hewlett-Packard/Agilent Technologies. Mr. Rusckowski is a member of the Board of Directors of Project Hope, a global health education and humanitarian assistance organization. He is also a member of the Board of Directors of the American Clinical Laboratory Association, and served as its Chairman from 2014-2017.
Mr. Rusckowski earned a Bachelor of Science degree in Mechanical Engineering from Worcester Polytechnic Institute and a Master of Science degree in Management from the Massachusetts Institute of Technology’s Sloan School of Management.CEO Cancer Gold Standard™
Gold Standard Employer
Since 2010Gold Standard Task Force Participation
Task Force Member(s): Maren S. Fragala, Ph.D, Director Healthy QuestLife Sciences Consortium
LSC Task Force Participation
Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world’s largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.
MEMBER SINCE 2024
Prashant Warier
Co-Founder and CEO
Prashant Warier is the co-founder and CEO of Qure.ai, the world’s most deployed medical imaging AI company. To date, Qure.ai’s innovative solutions have been deployed in more than 3100+ hospitals in 90+ countries.
With a career spanning over two decades, Prashant has successfully developed and commercialized various data science applications across multiple industries. He has 30+ patents to his name, his work has been published in top academic journals such as The Lancet and Nature, and he was awarded the Forbes India Leadership Award for his work in innovation in COVID diagnostics in 2021.
Prashant’s vision is to make healthcare more economically viable and universally attainable using technology. He is a respected proponent of AI for healthcare and regularly speaks around the world. Prashant Warier holds a PhD & MS in Operations Research from the Georgia Institute of Technology (USA) and has a bachelor's degree from the Indian Institute of Technology (IIT) Delhi.
Qure.ai
Qure.ai is a health tech company that uses deep learning and Artificial Intelligence (Al) to make healthcare more accessible and equitable for patients worldwide. Its solutions power the efficient identification and management of Tuberculosis (TB), Lung Cancer and Stroke to support clinicians and propel developments in the pharmaceutical and medical device industries. Qure.ai empowers healthcare by helping to identify conditions fast, prioritize treatment planning and ultimately improve quality of patient life. Qure.ai is headquartered in Mumbai, with regional team offices in New York and London.
MEMBER SINCE 2018
Teresa Graham
Chief Executive OfficerTeresa Graham started with Genentech in 2005 in product management. She became a Sales Manager in 2010 before taking over the Marketing Director role for Rituxan Immunology and subsequently for Actemra. Her responsibilities further expanded in 2013 when she became Senior Director for Field Reimbursement Management and then Lifecycle Leader for Actemra. By 2017, she was leading major aspects of the portfolio for Genentech until she was appointed to her current role in 2019 and relocated to Basel, Switzerland. A graduate of The George Washington University with a BBA in Business, Economics, and Public Policy, she is also a Global Board Member for the Healthcare Businesswomen’s Association, where she has served in multiple capacities for more than a decade.Project Data Sphere, LLC
an independent initiative of the Life Sciences ConsortiumImmune-related Adverse Events (irAE) InitiativeRoche Pharmaceuticals
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80’000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com. 
MEMBER SINCE 2023
Tim J. Gabel
President and Chief Executive OfficerTim J. Gabel became RTI International’s president and chief executive officer in 2022. Before becoming CEO in 2022, he served 10 years as executive vice president of Social, Statistical, and Environmental Sciences, the largest business unit within RTI.
As head of SSES, Mr. Gabel successfully grew the group from $391M to $667M in annual sponsored research, organically expanding existing divisions while overseeing the integration of acquisitions and development of strategic partnerships. Under Mr. Gabel’s executive oversight, a staff of 3,000 nationally recognized researchers, technologists, methodologists, and data scientists conducted over 1200 projects per year. Although varying in size and scope, common among those projects were complex multi-year, multi-million-dollar research studies that enabled federal, state, local, and international governments to make better policy decisions for all its citizens in the areas of health, education, justice, environment, and economic development. The number of RTI Fellows (RTI’s most accomplished scientists) in SSES nearly doubled under his leadership, and the organization witnessed a dramatic increase in major media outlet citations of their work.
A long-tenured RTI employee, Mr. Gabel has served at every level of RTI leadership, guiding various divisions and operating units to innovation-driven growth by maintaining a focus on operational excellence, client centricity, and a high commitment to quality.
Mr. Gabel is a member of the American Statistical Association, American Association for Public Opinion Research, and American Public Health Association. He co-edited the book The Essential Role of Language in Survey Research, published in 2020 by RTI Press. He holds adjunct appointments at the University of Wyoming and the Gillings School of Global Public Health at the University of North Carolina at Chapel Hill.
Mr. Gabel serves his community in a variety of volunteer roles, including board member of Go Global NC, board member of the United Way of North Carolina, Tocqueville Society member of the United Way of Alamance County, and member of the Board of Visitors for the University of Wyoming College of Arts & Sciences.CEO Cancer Gold Standard™
Gold Standard Employer
Since 2010Project Data Sphere, LLC
an independent initiative of the Life Sciences ConsortiumData Provider
Since 2018RTI International
RTI is an independent, nonprofit institute that provides research, development, and technical services to government and commercial clients worldwide. Our mission is to improve the human condition by turning knowledge into practice.
FOUNDING MEMBER
Chris Sarchi
Head of Oncology and TransplantMr. Chris Sarchi is responsible for all aspects of marketing and commercialization of oncology and transplant products at Sanofi Genzyme for North America.
Mr. Sarchi joined Sanofi Genzyme in December 2017, following a successful career in the pharmaceutical and biotechnology industry spanning over 25 years. During this time, he held various leadership positions in sales, marketing, strategic planning and new product development, as well as business unit leadership covering multiple therapeutic areas.
Prior to his current role, Mr. Sarchi was the Vice President and BU Head of Oncology and Biosimilars at Boehringer Ingelheim from 2013 to 2018. At BI, he was responsible for the initial build out of the oncology field commercial team. Mr. Sarchi has had additional leadership opportunities and experiences during his time at GSK, as well as Roche/Genentech.CEO Cancer Gold Standard™
Gold Standard Employer
Gold Standard Employer Since 2009 | Gold Standard China Employer Since 2015Gold Standard Task Force Participation
Chair 2011-2014; Co-Chair 2014-2016: Judy O’Hagan, Vice President Human ResourcesLife Sciences Consortium
LSC Task Force Participation
Task Force Member(s): Liz Zhou, MD, Director, North America Medical AffairsProject Data Sphere, LLC
an independent initiative of the Life Sciences ConsortiumData Provider
Staffing and project management support to Project Data Sphere, LLC, 2013-2015
Founding Team Leader Project Data Sphere, LLC: Charles Hugh-Jones, MD, FRCPSanofi
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patient’s needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme.
Sanofi US, with headquarters in Bridgewater, New Jersey, employs 17,000 professionals throughout the country. Our affiliate companies in the United States include Genzyme (rare diseases), Sanofi Pasteur (vaccines), Merial (animal health) and Chattem (consumer healthcare).
Through the Sanofi Foundation for North America, we strive to reduce healthcare inequalities in the U.S. by making strategic charitable donations and by establishing partnerships with Non-Government Organizations that have broad expertise in our long-term priorities.
At Sanofi, we act with our partners to protect health, enhance life and respond to the hopes and potential healthcare needs of 7 billion people around the world.
FOUNDING MEMBER
James H. Goodnight, PhD
Chief Executive OfficerAs the CEO of SAS, the world’s leading business analytics software vendor, Jim Goodnight has led the company since its inception in 1976, overseeing an unbroken chain of revenue growth and profitability unprecedented in the industry. He is recognized globally for being a trailblazer among companies that top great workplace rankings, including being No. 1 on several country and multinational lists. Harvard Business School named Goodnight a Great American Business Leader, and he was named one of America’s 25 Most Fascinating Entrepreneurs by Inc. magazine. A champion of education reform, Goodnight sees education as critical to the success of individuals, organizations and nations.CEO Cancer Gold Standard™
Gold Standard Employer
Since 2007"CEO Cancer Gold Standard accreditation is an extension of our ongoing commitment to the health and well-being of our employees. Together, the Gold Standard companies are making a strong statement that cancer can be prevented and lives can be prolonged."
James H. Goodnight, PhDGold Standard Task Force Participation
Task Force Member(s): Christy Crumpler, PHR, Senior Benefits AnalystLife Sciences Consortium
LSC Task Force Participation
Task Force Member(s): Gail Stephens, Vice President, Research and DevelopmentProject Data Sphere, LLC
an independent initiative of the Life Sciences ConsortiumExecutive Leadership Team
Jim Goodnight, PhD: Vice President, Project Data Sphere, LLCSAS
SAS is the leader in analytics. Through innovative analytics, business intelligence and data management software and services, SAS helps customers at more than 80,000 sites make better decisions faster. Since 1976, SAS has been giving customers around the world THE POWER TO KNOW®.
MEMBER SINCE 2008
Teresa Bitetti
President, Global Oncology Business UnitTeresa Bitetti is President of the Global Oncology Business Unit. She is responsible for oncology business activities in ten countries, including the U.S., Japan, U.K., Ireland, Germany, France, Italy, Spain, Portugal, and Canada.
Before joining Takeda, Teresa Bitetti was the Senior Vice President, Head of Worldwide Oncology Commercialization at Bristol-Myers Squibb. In this role, Teresa significantly enhanced the long-term strategic direction of the immuno-oncology portfolio. In addition, she further enhanced the model of collaboration with the R&D team to ensure the long-term success of its marketed and pipeline Oncology products. In the company, some of her key leadership roles have included Senior Vice President and Head of U.S. Oncology, President and GM of BMS Canada, and Worldwide Head of the BMS Virology business.
Prior to joining Bristol-Myers Squibb, Teresa held various roles of increasing responsibility at Mobil Oil Corporation, where she was part of the Capital Markets Group and was responsible for the investment of Mobil’s worldwide pension assets.
Over Teresa’s 20+ year career, she has been highly recognized for her adept ability to mobilize teams to deliver exceptional performance. Her notable awards include Medical Marketing Association 2003 Pharmaceutical Marketer of the Year Award and Medical Marketing & Media 2016 Hall of Femme Honoree.
Teresa holds a BA in Classical Civilization from Wellesley College and an MBA in Finance from Darden School of Business at University of Virginia.CEO Cancer Gold Standard™
Gold Standard Employer
Since 2009Gold Standard Task Force Participation
Task Force Member(s): Nancy M. Shostack, Director, Head of Benefits and MobilityLife Sciences Consortium
LSC Task Force Participation
Task Force Member(s): Dean Bottino, PhD, Clinical Translational Modeling & Simulation LeaderProject Data Sphere, LLC
an independent initiative of the Life Sciences ConsortiumData Provider
Since 2017Takeda Pharmaceuticals
At Takeda Oncology, the oncology business unit brand of Takeda Pharmaceutical Company Limited, we endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients.
This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, we are finding innovative ways to improve the treatment of cancer.
We’ve built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though we’ve made great strides in our fight against cancer, we are determined to do more — to work harder and to reach higher. We continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that we are today.
We know that our mission is not a quick or simple one, but we are up to the task: we aspire to cure cancer.
MEMBER SINCE 2023
Major General Elder Granger, MD
President and CEOSince 2009, Major General Granger has been the President and CEO of THE 5Ps, LLC, a health care, education, and leadership consulting organization in Colorado. Prior to his retirement from the US Army in 2009, Dr. Granger served as the Deputy Director and Program Executive Officer of the TRICARE Management Activity, Office of the Assistant Secretary of Defense (Health Affairs) in Washington, DC.
In that role, he was the principal advisor on health plan policy and performance at the Department of Defense. His experience, background, training, and expertise has required the building of strong, value-based relationships. He acquires clear guidelines to assess and determine “best value” and determines a process to ensure clear requirements and criteria to manage relationships to measurable, accountable outcomes.
Dr. Granger oversaw the acquisition, operation, and integration of TRICARE/DOD’s managed care program within the Military Health System, leading a staff of 1,800 in planning, budgeting, and executing a $22.5 Billion Defense Health Program.
Prior to joining TRICARE Management Activity, MG Granger led the largest U.S. and multi-national battlefield health system in our recent history while serving as Commander, Task Force 44th Medical Command and Command Surgeon for the Multinational Corps Iraq. He has led at every level of the Army Medical Department, with previous assignments across the United States, Europe, and Iraq.
Dr. Granger has received numerous awards, decorations, and honors, including the Defense Superior Service Medal, the Legion of Merit with three oak leaf clusters, the Bronze Star Medal, and the Meritorious Service Medal with four oak leaf clusters. He is board-certified by the American Board of Internal Medicine and the Board of Hematology and Oncology, certified Physician Executive by the Certifying Commission in Medical Management, certified by the American College of Healthcare Executives, and Certified in Medical Quality by the American Board of Medical Quality. CERT-certificate in Cybersecurity Oversight from Carnegie Mellon University, certified in Healthcare Compliance by HCCA and is a certified Compliance Officer by AAPC.The 5Ps, LLC
The 5Ps, LLC, a Service Disabled Veteran Owned Small Business (SDVOSB), provides cutting edge information technology solutions to commercial and government agencies. Our approach is to deliver value added services in the most cost effective way. We hire the most seasoned professionals, who are capable of handling and embracing the most complex issues our customers may encounter. Our employees take a proactive approach and are challenged daily to come up with creative ways to solve problems. Having solid management that provides innovative direction allows us to deliver a successful product to our clients in a timely manner and within their budgetary constraints.
The 5Ps, LLC is a leading provider of information technology services to commercial and government markets. Our approach to enable and deliver customer success is straight-forward and very effective.
We provide the most qualified staff at competitive rates while effectively serving our customers and embracing their challenges as our own. We increase delivered value by ensuring that our employees maintain a proactive, technical training schedule combined with the necessary tools to be successful.
1204 Village Market Place, Suite 288
Morrisville, NC 27560 (919) 531-3123 |
© COPYRIGHT 2024 CEO Roundtable on Cancer. ALL RIGHTS RESERVED.
|